Overview

Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201)

Status:
Completed
Trial end date:
2004-12-08
Target enrollment:
Participant gender:
Summary
To determine the efficacy and safety of an investigational compound (MK0966) for the prevention of prostate cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Rofecoxib